This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Myerburg, R. J. Articles by Castellanos, A. Search for Related Content PubMed PubMed Citation Articles by Myerburg, R. J. Articles by Castellanos, A.

Circulation, Vol 64, 280-290, Copyright © 1981 by American Heart Association

ARTICLES

Relationship between plasma levels of procainamide, suppression of premature ventricular complexes and prevention of recurrent ventricular tachycardia

RJ Myerburg, KM Kessler, I Kiem, KC Pefkaros, CA Conde, D Cooper and A Castellanos

We compared the relationship between plasma levels of procainamide and suppression or prevention of various forms of ventricular arrhythmias in 18 patients, six of whom had premature ventricular complexes (PVCs) during acute myocardial infarction (AMI), six of whom had PVCs in the setting of stable chronic ischemic heart disease (CIHD), and six of whom had recurrent symptomatic ventricular tachycardia (VT) with chronic PVCs between episodes of VT. The mean plasma level of procainamide required for 85% suppression of PVCs in the AMI patients was 5.0 +/- 0.5 micrograms/ml, while that required for the CIHD patients was 9.3 +/- 0.7 micrograms/ml (p less than 0.05). The mean plasma level required for prevention of spontaneous episodes of symptomatic sustained tachycardia in the VT group was 9.1 +/- 3.4 micrograms/ml, while the mean level required for 85% suppression of PVCs in the same patients was 14.9 +/- 3.8 micrograms/ml (p less than 0.01). In the VT group, PVC frequency was decreased by a mean of only 36% (range 11-63%) at plasma levels of procainamide sufficient to prevent spontaneous VT. The relationship between plasma levels of procainamide and PVC suppression appears to be different in AMI and CIHD patients; furthermore, a high degree of PVC suppression is not a necessary endpoint of antiarrhythmic therapy when attempting to protect patients against recurrent symptomatic VT.

This article has been cited by other articles:

				W. Hueb, G. Bellotti, E. Sosa, J. A. Ramires, P. L. da Luz, and F. Pileggi Ventricular Arrhythmias Induced by Programmed Ventricular Stimulation After Uncomplicated Myocardial Infarction Angiology, July 1, 1992; 43(7): 578 - 584. [Abstract] [PDF]

				R. J. Straka and P. S. Marshall The Clinical Significance of the Pharmacogenetics of Cardiovascular Medications Journal of Pharmacy Practice, January 1, 1992; 5(6): 337 - 361. [Abstract] [PDF]

				P. L. McCollam and J. L. Bauman New Concepts in Antiarrhythmic Drug Monitoring Journal of Pharmacy Practice, January 1, 1989; 2(6): 393 - 402. [PDF]

				R. J. Myerburg, K. M. Kessler, L. Zaman, C. A. Conde, and A. Castellanos Survivors of Prehospital Cardiac Arrest JAMA, March 12, 1982; 247(10): 1485 - 1490. [Abstract] [PDF]